Volume 77, Issue 6_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


The African Malaria Network Trust (AMANET), whose mission is to promote capacity strengthening of African malaria research institutions, was founded in 2002 and is currently focusing on malaria vaccine development. AMANET has trained over 900 African malaria researchers at workshops relevant to clinical trials of candidate malaria vaccines that will meet scientific, ethical, and international Good Clinical Practice standards. African centers selected for developing malaria vaccines initially undergo a needs assessment, followed by filling gaps in short- and long-term training, provision of essential equipment, and infrastructure improvement. Four centers from different malaria ecoepidemiologic settings are being strengthened; two of these have been approved for carrying out malaria vaccine trials. Researchers from prospective trial sites are mentored at northern institutions undertaking Phase 1a and/or 2a trials; five researchers are undergoing doctoral training. AMANET has sponsored one successful Phase 1b trial; three more are underway. Expert site audits will precede launch of phase 2b trials. Several lessons have been learned: the building of comprehensive capacity, essential for undertaking internationally acceptable trials including their sponsorship, is complex and costly. AMANET has spent over US$ 1 million on capacity strengthening of its leading trial center. Despite the high costs, development of three other sites is underway and there are plans to develop two more sites. To succeed, genuine north–south collaboration based on mutual trust and sharing of available information and responsibilities has been essential. AMANET as a sponsor has assumed roles usually reserved for the pharmaceutical industry, yet is operating where regulatory authorities are generally weak or wanting.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. UN Millennium Project, 2007. Millennium Development Goals (MDGs). Available at: http://www.unmillenniumproject.org/goals/index.htm. Accessed June 21, 2007.
  2. Engers HD and Godal T, 1998. Malaria vaccine development: current status. Parasitol Today 14 : 56–64.
    [Google Scholar]
  3. The Abuja Declaration and the Plan of Action, 2007. An Extract from the African Summit on Roll Back Malaria, Abuja, 25 April 2000 (WHO/CDS/RBM/2000.17). Available at: www.rbm.who.int/docs/abuja_declaration.pdf. Accessed June 21, 2007.
  4. P. Alonso, J. Sacarlal, J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa. Efficacy of the RTS,S/AS02A vaccine against infection and disease in young African children: synthesize controlled trial. Lancet 364 (Oct. 16):1411–1420.
    [Google Scholar]
  5. Teuscher T, Schellenberg JR, Bastos de Azevedo I, Hurt N, Smith T, Hayes R, Masanja H, Silva Y, Lopez MC, Kitua A, 1994. SPf66, a chemically-synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12 : 328–336.
    [Google Scholar]
  6. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, 1994. Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344 : 1175–1181.
    [Google Scholar]
  7. Trust Deed AMANET. Available at: http://www.amanet-trust.org/ext/news/AMANET_Trust_Deed.pdf. Accessed June 21, 2007.
  8. African Malaria Network Trust, 2007. Available at: http://www.amanet-trust.org/ext/reports/index.htm. Accessed June 21, 2007.
  9. International Conference on Harmonization of Good Clinical Practice, 1996. Available at: http://www.ich.org/cache/compo/276-254-1.html. Accessed June 21, 2007.
  10. Declaration of Helsinki, 2007. Available at: http://www.wma.net/e/policy/b3.htm. Accessed on June 21, 2007.
  11. European Malaria Vaccine Initiative, 2007. Available at: www.Emviorg.inforce.dk. Accessed on June 21, 2007.
  12. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O, 2007. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 25 : 2723–2732.
    [Google Scholar]

Data & Media loading...

  • Received : 25 Oct 2006
  • Accepted : 15 Aug 2007
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error